Big Update- Nasal vaccinations will soon become available in private hospitals.

 The health ministry has approved Bharat Biotech's intranasal vaccine against the viral infection as the number of Covid-19 cases rises in many regions of the world. The ministry announced on Friday that the needle-free vaccine will be made available at private centres and added to the Co-WIN platform soon.

According to officials, this will increase the nation's coverage of precautionary or booster dosage to the eligible population, which is currently at 27%.

nasal-vaccine-in-private-hospital-for-corona-in-India-2022-23



Conventional vaccines, which are typically administered as a shot in the muscle, function differently because they cause the bloodstream to circulate with antibodies. These antibodies are most effective at stopping the spread of the disease, although they frequently fall short in stopping an infection or transmission.


Since it is a new vaccine and is simple to give, experts are optimistic about its potential utility in reducing resistance to booster doses. According to data analysed by HT, 719 million of the 940 million people have not yet taken boosters.


The nasal vaccination is produced by Bharat Biotech in Hyderabad, which also produces Covaxin, one of the two anti-Covid vaccines that are frequently used as part of the national programme.

“We are future ready with the basket of vaccines and the expert committee today has approved the nasal vaccine. It is a nasal vaccine, therefore, there is no need to be jabbed with this new vaccine; just a drop in your nose and you are secured,” said Union health minister, Mansukh Mandaviya, in Rajya Sabha on Thursday.

The nasal vaccination was given national drug regulator approval in September.


The dosage was created by the Washington University School of Medicine in St. Louis, Missouri, and has been granted a production and distribution licence by Bharat Biotech and Precision Biologics, another American business. Logistics can be made simple because it can be stored at normal refrigerator temperature.

The company previously said in a statement that this vaccine candidate was tested in phase I, phase II, and phase III clinical trials with positive results, but none of the stages' specific data or studies have been made public.

People over 60 in particular have been encouraged by the authorities to take the third precautionary dose.

The prime minister also advised that the cautionary dose be encouraged, particularly for vulnerable and elderly people, during Thursday's review discussion on the Covid crisis.

Comments